A new company, founded by the team behind Juno Therapeutics, has granted a investment to Oscine Therapeutics that develops cell therapies against neurological disorders. Moreover, Oscine has given the investor an opportunity to buy the company when the phase I trials are finished.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.